Orkla ASA (ORK) Earnings Call Transcript & Summary

February 12, 2026

Oslo Bors NO Consumer Staples Food Products earnings 23 min

Earnings Call Speaker Segments

Annie Bersagel

executive
#1

Good morning, everyone, and welcome as we present Orkla's results for the fourth quarter. I'm Annie Bersagel, serving as Head of Investor Relations and Communications. Our President and CEO, Nils Selte, will kick things off with an overview of the quarter. Then our CFO, Arve Regland, will walk you through some additional detail on the financials for the quarter. Nils will return with some closing remarks before we move into the Q&A. A quick reminder about the Q&A: we'll start with a video Q&A featuring our analyst community, and then we'll take questions from the web. Feel free to submit your questions online at any point during the presentation, and we'll get to them afterward. With that, Nils, I'll hand things over to you.

Nils Selte

executive
#2

Thanks, Annie, and good morning to all of you. I'll start by covering the Q4 results, and then in my closing remarks I'll look back over the full year. For the quarter, organic growth came in at 4.5%, with both price and volume/mix making a contribution. Underlying EBIT, adjusted for the consolidated portfolio, rose by roughly 17%, and every portfolio company added to that on the positive side. Adjusted earnings per share were up 25% year-over-year, which reflects better profitability both in the consolidated portfolio and in Jotun. Organic growth in the fourth quarter of 2025 was the strongest we've seen since the fourth quarter of 2023, with a larger contribution from volume/mix. Volume/mix growth was delivered by most portfolio companies during the quarter. That includes all of the larger portfolio companies apart from Orkla Foods, which still has work to do in certain markets. This marked the 12th consecutive quarter of underlying EBIT adjusted growth. The uplift in Q4 came from bottom-line growth, cost reduction, and some periodization effects and non-recurring items when compared with last year. Double-digit EBIT adjusted growth was delivered by most portfolio companies during the period. Arve will go into more detail, but I'd like to highlight a few developments that drove our results. Jotun had another strong quarter, with underlying operating profit growth of 28%.

Nils Selte

executive
#3

Looking ahead to 2026, Jotun will mark a century since its founding, and we take pride in having shared in that journey over the last 50 years. Jotun's board plans to put forward a regular dividend of NOK 7,000 for each share. For Orkla, that works out to roughly NOK 1 billion. Orkla Snacks wrapped up a difficult period for the chocolate sector with a strong fourth quarter, posting 16% growth in underlying EBIT adjusted. Orkla Food Ingredients achieved 14% growth in underlying EBIT adjusted, helped by all three clusters and marking the completion of a successful turnaround at Sweet Ingredients in 2026. Measured on a rolling 12-month basis, the consolidated portfolio's EBIT adjust margin came in at 10.6%. That margin rose across the portfolio versus 2024, except at Orkla Health and Orkla Snacks. I'll wrap up this overview by updating you on the three-year financial target for the consolidated portfolio that we introduced at the 2023 Capital Markets Day. Underlying EBIT adjusted kept compounding beyond the target range, rising 6.6% for the year, on top of 17.3% growth in 2024. At 10.6%, the EBIT adjusted margin sits at the lower end of the target range. Return on capital employed climbed to 12.4%, helped by greater EBIT throughout the consolidated portfolio.

Nils Selte

executive
#4

I'll now pass things over to Arve, who will walk you through the financials in more detail.

Arve Regland

executive
#5

Thanks, Nils, and good morning. In the quarter, operating revenues rose 2% to 18.8 billion, and reported EBIT adjusted reached 2 billion, an increase of 12%. The group numbers are affected by softer sales at Orkla Real Estate relative to last year. Other income and expenses came to -151 million, which include restructuring costs at three portfolio companies as well as IPO-related expenses tied to the Orkla India listing. Those were partly offset by the gain on the sale of Orkla Food Ingredients' Icelandic operations. Profit from associates — mainly Jotun — was 505 million, up 36%. The 301 million estimated gain booked in discontinued operations concerns a favorable outcome in a tax dispute involving one of the divested hydropower assets. As Nils mentioned, adjusted EPS came in at NOK 1.74 per share, up 24%. Cash flow from operations was 7.8 billion in 2025, which is 0.3 billion lower than last year. Stronger EBIT growth was more than offset by higher net replacement investments across the portfolio companies. In the quarter, we received an extra dividend from Jotun of 438 million, which brings the total dividend received in 2025 to 1.4 billion. Cash flow before capital allocation finished at 6.9 billion, level with 2024.

Arve Regland

executive
#6

Now let's look at the capital allocation bridge, and I'll walk through a few specific developments from the quarter. Expansion CapEx stands at roughly 700 million year-to-date, and 250 million of that came in the fourth quarter. Most of it goes toward investments aimed at growing production capacity within Orkla Food Ingredients. Cash flow from company divestments came to 2 billion, driven chiefly by the Orkla India listing along with the sale of the two Icelandic businesses in Orkla Food Ingredients. Orkla keeps a strong balance sheet, with net debt at 14.2 billion — equivalent to 1.4 times EBITDA, or 0.9 times when Orkla Food Ingredients is left out. Turning to a bit more detail on the portfolio companies, beginning with Jotun, which closed out the year with yet another solid quarter, as Nils noted. Operating revenues rose 8.4% during the quarter, once adjusted for adverse currency translation effects. The top line benefited from volume growth and a bigger share of premium product sales within the decorative segment. Volumes were up across every segment apart from powder, and geographically, Northeast Asia contributed most to sales growth, helped by strong marine newbuild activity in China and Korea. Operating profit growth reached 28%, excluding adverse currency translation effects. The biggest drivers were higher sales volumes and an improved gross margin thanks to lower raw material costs.

Arve Regland

executive
#7

The portion of net profit attributable to Orkla rose 36%, reaching 505 million. Beyond the EBIT increase, net financial items came in better thanks to reduced interest costs, gains on currency hedging, and the divestment of Jotun's stake in an associate. Turning to the outlook, Jotun projects raw material prices will be flat in the first quarter. Across the full year, Jotun anticipates that sales growth will keep exceeding market growth. At the same time, they foresee that tougher competitive pressure on selling prices will pressure margins. Reported results are likewise expected to keep being hurt by currency translation effects. Organic growth at Orkla Foods came to 0.4%, split evenly between price and volume/mix. Volume/mix growth in Sweden carried on, and the ERP difficulties in the Czech Republic dating from Q3 were sorted out, with volume/mix growth turning positive. In Norway, volume/mix development was negative, partly because of reduced campaign activity. During the Capital Markets update, Orkla Foods laid out its prioritized growth platforms, which represent roughly 60% of the portfolio. Organic growth for the quarter was stronger in these platforms. EBIT growth stood at 3%, helped by periodization effects for SG&A compared with last year. Market input costs kept climbing during the quarter, and cost improvements only partly counterbalanced that effect.

Arve Regland

executive
#8

Meat, marine raw materials, and berries saw the sharpest inflation, and we anticipate that trend carrying on through 2026. Orkla Snacks posted organic growth of 7%, mainly driven by price in chocolate. It's good to see volume/mix growth at 1.7%, which closes out a tough year. Growth came from both the snacks and confectionery categories, whereas biscuits were a drag. Within confectionery, the BUBS U.S. rollout was the biggest contributor to positive volume/mix growth. Chocolate volumes keep falling. EBIT rose in all three categories. Key drivers were volume/mix growth in snacks and the BUBS U.S. launch, efficiency gains at the biscuit factory in Latvia, and ongoing cost cuts. Orkla Snacks anticipates input costs developing favorably in 2026. Organic growth at Orkla Home & Personal Care came in at -2.8%, reflecting one-time destocking at a Norwegian customer. Volume growth in Sweden and contract manufacturing partly offset that. Even so, market shares rose in the Norwegian, Swedish, and Finnish grocery markets. Underlying EBIT was up 4%, helped by lower fixed cost. Orkla Food Ingredients delivered organic growth of 8.3%, backed by solid price growth in all three clusters plus positive volume and mix development in Sweet and Plant-based.

Arve Regland

executive
#9

We saw underlying EBIT rise 13.6%, driven by ongoing growth in volume/mix, careful price management, and better operating leverage. Each of the three clusters posted positive underlying EBIT growth for the period. The Sweet cluster closed out the year with cumulative cost cuts in the high double-digit million range, consistent with the guidance we gave earlier. Orkla Health's organic growth came in at 5.2%, mainly driven by price in response to higher input costs in the food supplements category. Nutri-Care added a positive contribution as well, though sales fell in the functional personal care unit because of lower contract manufacturing tied to a contract set to expire in Q1 2027. A drop in sales to B2B customers in the oral care segment was another negative factor. The adjusted EBIT growth reflects the comparison against a tough quarter last year. Input prices for Orkla Health are expected to keep being hurt by the price trend for cod liver oil, a key input for food supplements in the omega-3 category. Keep in mind that in Q1, Orkla Health will face strong comparables. Orkla India posted organic growth of 8.1% for the quarter, led by volume growth of 10%. Price development was negative as key raw material costs kept falling.

Arve Regland

executive
#10

The convenience foods segment posted strong sales growth. In spices, volume gains kept outpacing the impact of price cuts that followed declines in raw material costs. Underlying EBIT rose 14.7%, driven by volume growth, cost control, and reduced advertising spend thanks to an earlier festive season. At the European Pizza Company, every business posted positive same-store revenue growth, with organic growth overall of 8.1% and consumer sales up 9.7%. Marketing efforts, menu innovation, and broader distribution were the main drivers. Underlying EBIT climbed 37%, helped by higher consumer sales and by the receivables write-off at New York Pizza last year. Finally, Orkla House Care saw negative organic sales tied to volume/mix in the UK and Benelux. Underlying profitability got a boost from lower costs and a larger share of sales from higher-margin products. In the Health and Sports Nutrition Group, organic growth on direct-to-consumer platforms was partly offset by lower B2B sales than a year ago. Underlying EBIT growth and cash conversion stayed high. With that, I'll hand it back to Nils for the closing remarks.

Nils Selte

executive
#11

Thank you, Arve. Looking back at 2025, we created organic value throughout the portfolio, posting 3.5% organic growth along with positive development in volume/mix. That converts into 6.6% growth in underlying EBIT adjusted, and we stayed focused on generating cash, finishing the year with cash conversion above 100% for the consolidated portfolio companies. Throughout the year we kept actively reshaping the portfolio, wrapping up the divestment of the hydropower assets and Pierre Robert Group in Q1, and listing Orkla India in November. The board plans to propose a total dividend of NOK 6 per share, which includes NOK 2 on top of the ordinary dividend, reflecting strong cash generation and a solid balance sheet. Beyond that, the NOK 4 billion share buyback program we announced at the third quarter presentation is still running. So far we have bought shares totaling roughly NOK 1.6 billion. 2026 marks the last year of our current three-year strategy period. Our priorities haven't changed: drive value in the existing portfolio and reduce complexity. We have increased our evaluation of value-adding structural opportunities, but as I've noted previously, we are also committed to walking away from any transaction that isn't in the best interest of Orkla's shareholders.

Nils Selte

executive
#12

As we move into 2026, we're getting ready for the next strategy period, and I'd like to ask you to save the date for our Capital Markets Day. The event will take place here in Oslo on December 1st this year. What we aim to do is lay out Orkla's strategic direction through 2030 as an industrial investment company centered on brands and consumer-oriented businesses. With that, Arve and I are now glad to take your questions.

Annie Bersagel

executive
#13

Thanks for joining again. The Q&A portion can start now. If you’d like to ask something, please lift your hand, and I’ll bring you in. Don’t forget to switch your camera on and take yourself off mute. It appears the opening question comes from Petter Nystrøm at ABG Sundal Collier.

Petter Nystrøm

analyst
#14

Appreciate you taking my question. I came in a bit late to the call, so apologies if this was already covered. You brought up some favorable phasing effects and some reduced SG&A expenses at certain portfolio companies. Could you put numbers to those? Thank you.

Arve Regland

executive
#15

Yeah. We saw some particular one-off items at Orkla Health and European Pizza Company in Q4 '24, and those were also covered in the pre-close information. On top of that, there were phasing and periodization effects across a few of the portfolio companies from one quarter to another. Even so, I'd say that most of the EBIT growth — a clear majority of it — comes from underlying profitability relative to the same quarter last year.

Petter Nystrøm

analyst
#16

Thanks. I’ll rejoin the queue.

Annie Bersagel

executive
#17

I don't see any further video questions coming in. There's one submitted online from Ole Martin Westgaard at DNB Carnegie, though it seems to be the same one, asking us to quantify the periodization effects and non-recurring items. Are there any other questions? It looks like we have one from Håkon Fuglu at SEB.

Håkon Fuglu

analyst
#18

Morning, and thanks for taking my question. Could you quantify what BUBS has contributed to sales in the U.S., and how that will progress going forward?

Nils Selte

executive
#19

I'd say first off, we're really pleased with how the launch has gone. We're collaborating very closely and well with Mount Franklin Foods, our partner in the US. BUBS has secured a broad nationwide listing through the biggest retailers in the US. In Q4, performance came in a bit better than what we guided through Q3, though we won't put a number on it right now. That said, we'll keep investing behind BUBS in the US. We believe there's great potential for that product in the US, and we will invest behind it. As we mentioned in Q3, we don't expect any major impact on EBIT performance for Orkla Snacks over the coming quarters.

Håkon Fuglu

analyst
#20

I appreciate that.

Annie Bersagel

executive
#21

Is there anything else on video? That seems to be the final video question, and it looks like no further questions have come in on the web. Before we wrap up, let me remind everyone that our Annual General Meeting takes place on April 23rd, and we'll report first quarter results on May 20th. With that, thanks for joining, and please enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.